Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Yutaka Nakae
Randomized Phase II Trial of Survivin 2B Peptide Vaccination for Patients With HLA-A24-positive Pancreatic Adenocarcinoma
Cancer Science
Cancer Research
Medicine
Oncology
Related publications
HLA-A24 and Survivin: Possibilities in Therapeutic Vaccination Against Cancer
Journal of Translational Medicine
Biochemistry
Medicine
Genetics
Molecular Biology
A Phase I Clinical Trial of Vaccination With KIF20A-derived Peptide in Combination With Gemcitabine for Patients With Advanced Pancreatic Cancer
Journal of immunotherapy (Hagerstown, Md. : 1997)
Cancer Research
Allergy
Immunology
Pharmacology
Phase I Clinical Trial of Multiple-Peptide Vaccination for Patients With Advanced Biliary Tract Cancer
Journal of Translational Medicine
Biochemistry
Medicine
Genetics
Molecular Biology
Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Randomized Phase II Trial Designs With Biomarkers
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Erratum To: Phase I Clinical Trial of Vaccination With URLC10-derived Peptide for Patients With Advanced Esophageal Cancer
Esophagus
Gastroenterology
Phase II Trial of Vatalanib in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma After First-Line Gemcitabine Therapy (PCRT O4-001)
Cancer Chemotherapy and Pharmacology
Cancer Research
Toxicology
Oncology
Pharmacology
Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated After Chemoradiotherapy and an 8-Year Update on a Phase I/Ii Trial
Clinical Cancer Research
Cancer Research
Oncology
Identification of a Novel HLA-A24-restricted Cytotoxic T Lymphocyte Epitope Peptide Derived From Mesothelin in Pancreatic Cancer
Oncotarget
Oncology
